1.32
price up icon0.00%   0.00
pre-market  Vorhandelsmarkt:  1.27   -0.05   -3.79%
loading
Schlusskurs vom Vortag:
$1.32
Offen:
$1.35
24-Stunden-Volumen:
1.13M
Relative Volume:
1.07
Marktkapitalisierung:
$17.44M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.51M
KGV:
-1.00
EPS:
-1.32
Netto-Cashflow:
$-8.02M
1W Leistung:
-1.49%
1M Leistung:
+9.09%
6M Leistung:
-2.94%
1J Leistung:
+57.24%
1-Tages-Spanne:
Value
$1.26
$1.36
1-Wochen-Bereich:
Value
$1.2333
$1.39
52-Wochen-Spanne:
Value
$0.58
$3.80

Hoth Therapeutics Inc Stock (HOTH) Company Profile

Name
Firmenname
Hoth Therapeutics Inc
Name
Telefon
(646)756-2997
Name
Adresse
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Name
Mitarbeiter
3
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
HOTH's Discussions on Twitter

Vergleichen Sie HOTH mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
HOTH
Hoth Therapeutics Inc
1.32 17.70M 0 -7.51M -8.02M -1.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2019-10-15 Eingeleitet The Benchmark Company Speculative Buy

Hoth Therapeutics Inc Aktie (HOTH) Neueste Nachrichten

pulisher
Jul 22, 2025

Hoth Therapeutics shares fall 1.52% intraday after signing VA research deal to advance GDNF as breakthrough therapy for obesity and fatty liver. - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Hoth Therapeutics partners with VA to test GDNF therapy for obesity By Investing.com - Investing.com South Africa

Jul 22, 2025
pulisher
Jul 22, 2025

Hoth Therapeutics partners with VA to test GDNF therapy for obesity - Investing.com Australia

Jul 22, 2025
pulisher
Jul 22, 2025

New Weight Loss Drug Challenger GDNF Takes On Semaglutide in Landmark VA Obesity Study - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

Why Hoth Therapeutics Inc. stock attracts strong analyst attentionElite Investor Club - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

Hoth Therapeutics Inc. Stock Analysis and ForecastMarket-crushing stock picks - Autocar Professional

Jul 22, 2025
pulisher
Jul 21, 2025

Is Hoth Therapeutics Inc. a good long term investmentUnprecedented growth rates - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

What analysts say about Hoth Therapeutics Inc. stockFree Stock Selection - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

What drives Hoth Therapeutics Inc. stock pricePowerful profit generation - printweek.in

Jul 20, 2025
pulisher
Jul 15, 2025

How Hoth Therapeutics Inc. stock performs during market volatilitySwing Trade Signals - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Hoth Therapeutics Inc. stock price move sharplyDaily Volume Leaders - Newser

Jul 15, 2025
pulisher
Jul 05, 2025

Hoth Therapeutics (NASDAQ:HOTH) Upgraded by Wall Street Zen to Hold Rating - Defense World

Jul 05, 2025
pulisher
Jun 25, 2025

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market | Daily Courier - FinancialContent

Jun 25, 2025
pulisher
Jun 24, 2025

Hoth Therapeutics Advances HT-001 for Cancer Treatment - TipRanks

Jun 24, 2025
pulisher
Jun 24, 2025

HT-001's Breakthrough in Oncology Supportive Care: A Game-Changer for Hoth Therapeutics? - AInvest

Jun 24, 2025
pulisher
Jun 24, 2025

Hoth Therapeutics stock rises after positive Phase 2a trial results - Investing.com India

Jun 24, 2025
pulisher
Jun 23, 2025

Leading Cancer Experts Reveal Phase 2 Data for Revolutionary Skin Toxicity Treatment HT-001 - Stock Titan

Jun 23, 2025
pulisher
Jun 20, 2025

Hoth Therapeutics Regains Nasdaq Compliance on June 18 - TipRanks

Jun 20, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics reports positive preclinical safety data for HT-KIT By Investing.com - Investing.com South Africa

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Regains Nasdaq Compliance - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Just Cleared Critical Nasdaq Hurdle: What This Means for Its $1B+ Biotech Pipeline - Stock Titan

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT Dose-Dependent Liver Activity with No Observed Toxicity Supports Ind Pathway - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics (HOTH) Reports Promising Preclinical Outcomes for Cancer Drug | HOTH Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cancer Drug Breakthrough: Hoth's HT-KIT Achieves Perfect Safety Profile Ahead of Clinical Trials - Stock Titan

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 16, 2025

Market Momentum Report: Hoth Therapeutics Inc (HOTH)’s Negative Close at 1.30 - DWinneX

Jun 16, 2025
pulisher
Jun 16, 2025

Hoth Therapeutics Joins 20,000 Biotech Leaders at World's Largest Industry Convention - Stock Titan

Jun 16, 2025
pulisher
Jun 13, 2025

Hoth Therapeutics (HOTH) Secures Patent for HT-KIT Platform in J - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics secures Japanese patent for mast cell disease treatment By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics secures Japanese patent for mast cell disease treatment - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics Secures 15-Year Japanese Patent Protection for Revolutionary Mast Cell Disease Platform - Stock Titan

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics (HOTH) Receives 'Buy' Rating from D. Boral Capital | HOTH Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics plans expanded access program for cancer skin toxicity drug - Investing.com India

Jun 12, 2025
pulisher
Jun 11, 2025

Hoth Therapeutics plans expanded access program for cancer skin toxicity drug By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

Hoth Therapeutics, Inc. Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Hoth Therapeutics Launches Expanded Access Initiative For HT-001 - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

HOTH Seeks Expanded Access for HT-001 to Address Skin Toxicities | HOTH Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Hoth Expands Access to Cancer Skin Toxicity Treatment HT-001 in Phase 2a Success | HOTH Stock News - Stock Titan

Jun 11, 2025
pulisher
Jun 05, 2025

Hoth Therapeutics advances with HT-001 oncology skin care treatment By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Hoth Therapeutics advances with HT-001 oncology skin care treatment - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities - PR Newswire

Jun 05, 2025

Finanzdaten der Hoth Therapeutics Inc-Aktie (HOTH)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):